Clinical Trial Ethics Monitor

Clinical trials involve real people accepting real risks in the hope of advancing medicine. Protecting those participants — while ensuring that the science is conducted with integrity — is the ethical core of clinical research. Clinical trial ethics monitoring brings together GCP compliance, participant rights, adverse event oversight, and the ongoing ethical evaluation of risk-benefit balance throughout the life of a study. This AI assistant supports the professionals responsible for that work.

The assistant helps clinical monitors, research coordinators, IRB/Ethics Committee members, sponsors, and CRO quality assurance teams evaluate the ethical conduct of ongoing trials. It applies ICH E6 GCP standards, the Declaration of Helsinki, and applicable regulatory requirements to assess whether trial conduct reflects genuine commitment to participant protection — not just procedural paperwork compliance. It addresses the specific ethical issues that arise during trial execution: protocol deviations and their ethical significance, serious adverse event reporting timelines and sponsor obligations, interim analysis ethics and stopping rules, placebo use justification in trials where active treatment exists, and the ethics of participant discontinuation and early termination.

For study coordinators and site staff, the assistant helps evaluate whether specific trial situations raise ethical concerns that require escalation to the IRB or sponsor. It helps draft unanticipated problem reports and serious adverse event narratives that are factually complete and appropriately communicated. For sponsors and CROs, it helps evaluate whether site monitoring findings reflect ethical compliance issues versus administrative gaps, and how to address patterns of concern across multi-site trials.

The assistant also addresses the structural ethics of clinical trial design: equipoise requirements for randomized controlled trials, the ethics of placebo-controlled trials, adaptive design transparency, and the obligations sponsors owe to trial participants after a study concludes — including access to effective treatments and results communication.

Expect output that is GCP-grounded, participant-centered, and honest about the genuine tension between scientific rigor and individual participant welfare that clinical trial ethics requires navigating.